Claims
- 1. A method for treating and/or preventing nasal congestion associated with allergic and inflammatory conditions of the airway passages in a human in need thereof comprising administering to said human an amount of desloratadine effective for such treating and/or preventing.
- 2. The method of claim 1, wherein the amount of desloratadine is about 2.5 mg/day to about 45 mg/day.
- 3. The method of claim 2, wherein the amount of desloratadine is about 5 mg/day to about 15 mg/day.
- 4. The method of claim 3, wherein the amount of desloratadine is about 5 mg/day to about 10 mg/day.
- 5. The method of claim 1, wherein the allergic and inflammatory condition is seasonal allergic rhinitis, perennial allergic rhinitis, sinusitis, or allergic asthma.
- 6. A method of treating and/or preventing nasal blockage associated with allergic and inflammatory conditions of the airway passages in a human in need thereof comprising administering to said human an amount of desloratadine effective for such treating and/or preventing.
- 7. The method of claim 6, wherein the amount of desloratadine is in the range of about 2.5 mg/day to about 45 mg/day.
- 8. The method of claim 7, wherein the amount of desloratadine is about 5 mg/day to about 15 mg/day.
- 9. The method of claim 8, wherein the amount of desloratadine is about 5 mg/day to about 10 mg/day.
- 10. A method of treating and/or preventing severe nasal blockage associated with allergic and inflammation conditions in a human in need thereof comprising administering to said human an amount of desloratadine effective for such treating and/or preventing in combination with one or more additional decongestants.
- 11. The method of claim 10 wherein the amount of desloratadine is about 2.5 mg/day to about 45 mg/day.
- 12. The method of claim 11, wherein the amount of desloratadine is about 5 mg/day to about 15 mg/day.
- 13. The method of claim 12, wherein the amount of desloratadine is about 5 mg/day to about 10 mg/day.
- 14. The method of claim 10, wherein said decongestant is pseudoephedrine.
- 15. The method of claim 14, wherein said pseudoephedrine is present in an amount to provide decongestant effect with elimination or reduction of an adverse side effect associated therewith.
- 16. The method of claim 15, wherein said adverse side effect is insomnia, dizziness, weakness, tremor, or arrhythmia.
- 17. The method of claim 10, wherein the amount of desloratadine is about 5 mg/day.
- 18. The method of claim 10, wherein the amount of desloratadine is about 6 mg/day.
- 19. A method for treating and/or preventing nasal congestion associated with allergic and inflammatory conditions of the airway passages in a human in need thereof comprising administering to said human an amount of antihistamine effective for such treating and/or preventing.
- 20. The method of claim 19, wherein the antihistamine is selected from the group consisting of loratadine, cetirizine, fexofenadine, ebastine, astemizole, norastemizole, epinastine, efletirizine or a pharmaceutically acceptable salt thereof.
- 21. The method of claim 20, wherein the antihistamine is loratadine.
- 22. The method of claim 21, wherein the amount of loratadine is about 10 mg/day.
- 23. The method of claim 19, wherein the allergic reaction is seasonal allergic rhinitis, perennial allergic rhinitis, sinusitis, or allergic asthma.
- 24. A method of treating and/or preventing nasal blockage associated with seasonal allergic rhinitis in a human in need thereof comprising administering to said human an amount of antihistamine effective for such treating and/or preventing.
- 25. The method of claim 24, wherein the antihistamine is selected from the group consisting of loratadine, cetirizine, fexofenadine, ebastine, astemizole, norastemizole, epinastine, efletirizine or a pharmaceutically acceptable salt thereof.
- 26. The method of claim 25, wherein the antihistamine is loratadine.
- 27. The method of claim 26, wherein the amount of loratadine is about 10 mg/day.
- 28. A method of treating and/or preventing severe nasal blockage associated with allergic and inflammation conditions in a human in need thereof comprising administering to said human an amount of antihistamine effective for such treating and/or preventing in combination with one or more additional decongestants.
- 29. The method of claim 28, wherein the antihistamine is selected from the group consisting of loratadine, cetirizine, fexofenadine, ebastine, astemizole, norastemizole, epinastine, efletirizine or a pharmaceutically acceptable salt thereof.
- 30. The method of claim 29, wherein the antihistamine is loratdine.
- 31. The method of claim 30, wherein the amount of loratadine is about 10 mg/day.
- 32. The method of claim 28, wherein said decongestant is pseudoephedrine.
- 33. The method of claim 32, wherein said pseudoephedrine is present in an amount to provide decongestant effect with elimination or reduction of an adverse side effect associated therewith.
- 34. The method of claim 28, wherein said adverse side effect is insomnia, dizziness, weakness, tremor, or arrhythmia.
- 35. The method of claim 28, wherein the antihistamine is cetirizine.
- 36. The method of claim 35, wherein the amount of ceterizine is about 5 mg/day.
- 37. The method of claim 35, wherein the amount of ceterizine is about 10 mg/day.
- 38. The method of claim 28, wherein the antihistamine is fexofenadine.
- 39. The method of claim 38, wherein the amount of fexofenadine is about 180 mg/day.
- 40. The method of claim 38, wherein the amount of fexofenadine is about 60 mg/day.
- 41. The method of claim 38, wherein the amount of fexofenadine is about 30 mg/day.
Parent Case Info
[0001] This application claims formal benefit of priority to Provisional U.S. patent application Ser. Nos. 60/299,636 and 60/299,637, both of which were filed Jun. 20, 2001.